Balancing patient value and payer cost in hematologic malignancies: can it be done?

Expert Rev Pharmacoecon Outcomes Res. 2018 Apr;18(2):123-126. doi: 10.1080/14737167.2018.1444478. Epub 2018 Mar 13.
No abstract available

Keywords: Cost-effective; leukemia; lymphoma; multiple myeloma; pharmacogenomics.

Publication types

  • Editorial

MeSH terms

  • Antineoplastic Agents / economics
  • Antineoplastic Agents / therapeutic use*
  • Cost-Benefit Analysis
  • Drug Approval*
  • Hematologic Neoplasms / drug therapy*
  • Humans
  • United States
  • United States Food and Drug Administration

Substances

  • Antineoplastic Agents